“We also found that socioeconomic disparities, which disproportionately affected African American patients with kidney cancer, play an important role in impacting survival in RCC,” says Nirmish Singla, MD, MSc.
In this video, Nirmish Singla, MD, MSc, shares notable findings from the recent Urologic Oncology paper, “Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma.” Singla is an associate professor of urology and oncology in the Brady Urological Institute at Johns Hopkins University in Baltimore, Maryland.
We started first off by analyzing all comers with RCC, and we stratified the population by essentially African American race vs Caucasian race. And then we went on and performed some additional sub analyses that were matched by stage. This included, on one end of the spectrum, patients who had non-metastatic small renal masses. And then on the complete other end of the spectrum, we also looked at patients who were diagnosed with metastatic disease at presentation. Then we also did some sub analyses by histologic subtypes in RCC. These included patients with clear cell RCC, which is the most common subtype of RCC, and also papillary RCC, which, interestingly, proportionately seems to affect African Americans at a higher rate compared with their Caucasian counterparts. And so overall, what we had found from our analysis was that African American patients with RCC seem to exhibit worse survival outcomes compared with Caucasian patients. And this was evident across all stages and histologies. And interestingly, also, this is despite the observation that African Americans were younger and also diagnosed at a relatively earlier stage. Furthermore, and what was striking about our study is that we also found that socioeconomic disparities, which disproportionately affected African American patients with kidney cancer, play an important role in impacting survival in RCC, and these are likely the factors that are driving inequalities in access to care and seem to be more magnified in patients who have advanced cases that would often benefit from this multidisciplinary expertise.
This transcript was edited for clarity.
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
Live bacterial supplementation may improve TKI-based treatment efficacy in kidney cancer
June 30th 2024CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD.
Pembrolizumab/lenvatinib labels updated to include KEYNOTE-B61 data in non-ccRCC
June 28th 2024"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.